ABBOTT PARK, IL: Pharmaceutical company Abbott Laboratories is having discussions with MSLGroup about project work for its prescription arthritis medication Humira.
Raquel Powers, director of international public affairs for the proprietary pharmaceuticals division of Abbott, said the company is talking to MSL about potentially working to promote the drug. She declined to give further details.
It is understood that the assignment is for global disease-education work on rheumatoid arthritis and psoriasis. The responsibilities will include global patient surveys and traditional pharmaceutical PR efforts for the drug.
MSL representatives declined to comment on the potential projects.
Abbott is planning to split into two separate, publicly traded companies when it spins off its AbbVie pharmaceutical unit in January.
Following the business deal, Abbott will oversee the company's proprietary pharmaceutical products, and the newly created AbbVie business will encompass research-based pharmaceuticals. Humira will fall under AbbVie.
In September, the FDA approved the expanded use of Humira to include the treatment of moderate-to-severe ulcerative colitis in adults. Humira is also approved to treat rheumatoid arthritis, psoriatic arthritis, and juvenile idiopathic arthritis, among other diseases.
As of April, pharmaceutical analysts said that Humira, which is worth $9 billion in sales, would be the world's best-selling medicine this year.